Arcellx Inc
Change company Symbol lookup
Select an option...
ACLX Arcellx Inc
ASO Academy Sports and Outdoors Inc
PRI Primerica Inc
UAA Under Armour Inc
TGLVY Top Glove Corporation Bhd
ACQRU Independence Holdings Corp
KEGS 1812 Brewing Company Inc
PHUN Phunware Inc
WFC Wells Fargo & Co
XRX Xerox Holdings Corp

Health Care : Biotechnology |
Company profile

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company is advancing its CART-ddBCMA product through its iMMagine Phase 2 pivotal trial in patients with relapsed or refractory (r/r) multiple myeloma (MM). The Company is also advancing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the ARC-T cells, its D-Domain based universal CAR-T cells that are designed to activate only when bound to a SparX protein that is bound to an antigen on a cell. It is also exploring indications in solid tumors.

Day's Change
0.30 (1.52%)
B/A Size
Day's High
Day's Low

Today's volume of 254,721 shares is on pace to be in-line with ACLX's 10-day average volume of 426,448 shares.

  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    1:55p ET 12/02/22
  • Last (size)
  • 52-Wk Range
    6.04 - 26.91
  • (05/17/22 - 06/10/22)
  • 90.4%
  • Market Cap
  • Shares Outstanding
  • -4.15
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 92.75
  • (% of float 11/15/22)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.